MSDx Welcomes David McCaleb to its Board of Directors

TUCSON, AZ, July 11, 2013 – MSDx, Inc., announced today that David McCaleb has joined its Board of Directors.
With over thirty years of experience in leading pharmaceutical companies and biotech start-ups, his successful
track record in commercialization and fundraising will augment the MSDx team.
During Mr. McCaleb’s career he played a central role in the establishment of commercialization infrastructure at
several highly successful companies including Amgen, Cephalon, Gilead and CV Therapeutics. He has directed the
worldwide introduction of billion-dollar products, including Merck’s Vasotec® and Amgen’s Neupogen®. At CV
Therapeutics, he led the growth of the operations from 1 employee to almost 500 around the country. There he
managed the launch of their first product, Ranexa®. Currently he is the Chief Executive Officer of Susavion
“We are honored to have David McCaleb join our Board,” says Marie Wesselhoft, President of MSDx. “Launching a
‘Personalized Medicine’ solution in today’s market requires knowledge of both the pharmaceutical and diagnostic
markets. It calls for innovative business models and launch strategies. David McCaleb’s tremendous operational
experience and successful track record bring just the skill set that MSDx needs at this phase in its development.”
Mr. McCaleb remarks, “My career has been spent providing physicians with breakthrough products to better care
for their patients. The diagnostic tools under development by MSDx aim to fill a significant void in patient
management. I have been particularly impressed with the unique power of the MSDx WINDOW INTO THE
biomarker technology. I believe these tests can provide the neurologist with an important source of new
data to help address the difficult decisions they face every day.”
About MSDx, Inc.
MSDx discovered a novel source of blood-based biomarkers that can offer a real-time view of disease activity in the
brain. The company refers to its proprietary, patent-pending approach as WINDOW INTO THE BRAINTM. Multiple
Sclerosis is the first disease of focus for the company. Ultimately, this technology may be applied in other brain
diseases such as Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury. Ms. Wesselhoft says,
“Our products wil provide clinicians with important information on disease activity earlier in the disease process.
This critical data can aid in determining whether drug therapy is working for an individual patient, and offer insights
into personalized patient care over time.”
MSDx is developing Laboratory Developed Tests (LDT) as well as In Vitro Diagnostic (IVD) blood tests for brain
diseases. The company is located in Tucson at the University of Arizona's Tech Park business incubator called the
Arizona Center for Innovation (AzCI). Please visifor more information about the company and their
patent-pending technology.
Media Contact:
Marie Wesselhoft,


Microsoft word - final_070906.doc

Epidémiologie - Evolution naturelle - Diagnostic - Thérapie A. Bitton a , R.M.Müller b , S. Madersbacher c , U.E. Studer b Une meilleure compréhension de la pathogenèse, ainsi que de l’évolution naturelle de l’hyperplasie bénigne de la prostate (HBP), doublée de moyens diagnostiques et thérapeutiques plus performants, permettent, de nos jours, une meilleure prise en charge des pa

Clomid serophene

S o u t h M i a m i O B - G Y N A s s o c i a t e s H elp fu l Res ou rces This fact sheet is meant to provide you with basic information about this medicine. As usual, any further questions should be discussed with your doctor or p 1. What is Serophene/Clomid? It is the brand name for Clomiphene citrate, which is a medicine that has been on the market since the 1960s and introd

Copyright © 2010-2014 Metabolize Drugs Pdf